Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Authors:
Open Access
- 1 August 2015
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 8 (9) , 1157-1165
Abstract
No abstract availableKeywords
Funding Information
- Abbott Vascular
- St. Jude Medical
- Boston Scientific Corporation
This publication has 23 references indexed in Scilit:
- Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trialsEuroIntervention, 2012
- NeoatherosclerosisCirculation: Cardiovascular Interventions, 2012
- Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes MellitusCirculation, 2011
- 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily PracticeJACC, 2011
- Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting StentsJACC: Cardiovascular Interventions, 2011
- Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)The American Journal of Cardiology, 2011
- The Pathology of Neoatherosclerosis in Human Coronary ImplantsJACC, 2011
- Coronary StentsJACC, 2010
- Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting StentsJACC, 2008
- Pathological Correlates of Late Drug-Eluting Stent ThrombosisCirculation, 2007